The future belongs to precision formulations that treat personal and societal health issues.
If you’re curious about where the cannabis industry is headed, it might be time to see a doctor. A good place to start would be the distinguished group of California Board Certified Physicians on Juva’s Medical Advisory Board. At Juva, we’ve assembled a panel of leading clinicians and researchers to help change the entire dynamic around cannabis.
Here’s our diagnosis.
The medical profession needs to be more informed in recommending cannabis to patients who could benefit from it. Clinicians need the knowledge to know what works for what kind of ailments. They need research-driven, effect-based formulations that have been effective through patient reported outcomes, so they can trust their recommendations to patients. Only then can they begin to close the knowledge gap between physicians and patients – which today resembles a “don’t ask, don’t tell”situation where even talking about how cannabis can help is still, in too many instances, considered taboo.
The team of cannabis pioneers and acclaimed medical professionals at Juva are committed to giving physicians what they need to help their patients take advantage of the many benefits of cannabis. We serve the recreational market well, and will continue to do so. At the same time, Juva is laying the groundwork through investments in developing a portfolio of precision cannabis products specifically formulated to treat some of medicine’s most pressing health and wellness challenges.
The New Frontier of Evidence-Based Formulations
Learn and improve. That’s how cannabis will ultimately become an integral part of traditional health care systems. By focusing on patient-reported outcomes and using research to drive better product formulations. At Juva, that process is built into our Vertical Integration approach. It’s a closed loop, where every step of the process, from cultivation to retail, is owned and operated and meticulously monitored by the same team. As a loop, however, and unlike most cannabis companies, it doesn’t end at the sale. Through patient monitoring and tracking, Juva will be making constant adjustments to the compounds in their formulations to keep prescription-grade products at the leading edge of effectiveness.
Changing The Medical and Cannabis Industry,
One Patient At A Time
“It’s very intentional to focus on effects through research and to continually adjust product development,” says Juva Clinical Research Adviser Peter Beitsch, MD. “We have a highly credentialed team of leading clinicians and experienced researchers,” according to Dr. Beitsch. “Our goal is to drive physician adoption by giving them the confidence to recommend cannabis based on solid, real-world research.”
Juva Founder, CEO and Chairman Doug Chloupek takes it a step further. “We’re looking beyond adult use,” he says. “By offering an alternative to single compound pharmaceutical products, we target specific ailments to really make a difference in how people feel.” This is where Juva sees the greatest opportunity in the cannabis marketplace. “Our research shows that by identifying five target ailments and treating just 1% of the newly diagnosed in a year – that’s a $300 million annual market in California alone. The demand is there, and nobody else has the kind of expertise we’ve put together to make it work.”
Dr. Rakesh Patel, Medical Advisor agrees. “Our goal is to use effect-based data collection to create research-grade formulations that are reproduceable with predictable outcomes. If we can do that, we could change the entire dynamic in the cannabis industry and in healthcare.” But he’s quick to point out that the real benefits are more personal. “Ideally,” he says, “we are able to improve an individual’s quality of life and, in turn, help a lot more people feel better. If we can impact some of the more pressing medical challenges, particularly around pain management and opioid abuse, we should be able to make a positive societal impact as well.”
